• Memora Health and NorthShore Edward-Elmhurst Health Venture Capital - Part 2

  • Feb 16 2023
  • Durée: 17 min
  • Podcast

Page de couverture de Memora Health and NorthShore Edward-Elmhurst Health Venture Capital - Part 2

Memora Health and NorthShore Edward-Elmhurst Health Venture Capital - Part 2

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • This episode continues the discussion with two entrepreneurs who are leading efforts to bring care seamlessly to the home through a digital approach.

    Guest speakers: Manav Sevak, BS Founder and Chief Executive Officer Memora Health

    Melissa Cohen, BS Managing Director NorthShore Edward-Elmhurst Health Venture Capital

    Moderators: Crystal Mullis, RN, MBA, MHA Vice President, Member Backed Ventures Vizient

    Heather Ramirez, MS Ventures Director Vizient

    Show Notes:

    [01:45] Extending the reach of Memora Health through partnerships

    [05:06] “Mass personalization”

    [07:25] Easier ways for providers and patients to get in touch

    [10:39] Meeting future challenges

    Links | Resources:

    Vizient Member-Backed Ventures email: mbv.info@vizientinc.com

    Website for Memora Health: https://www.memorahealth.com/

    Website for NorthShore University HealthSystem: https://www.northshore.org

    Website for Edward-Elmhurst Venture Capital: https://eeh.vc

    Melissa Cohen’s email: melissa.cohen@eehealth.org

    Manav Sevak’s email: manav@memorahealth.com

    Subscribe Today!

    Apple Podcasts

    Amazon Podcast

    Spotify

    Google Podcasts

    Stitcher

    RSS Feed
    Voir plus Voir moins
activate_primeday_promo_in_buybox_DT
Gestion et leadership Économie Troubles et maladies Hygiene & Healthy Living
Voir plus Voir moins

Ce que les auditeurs disent de Memora Health and NorthShore Edward-Elmhurst Health Venture Capital - Part 2

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.